UA111145C2 - Фармацевтична композиція - Google Patents

Фармацевтична композиція

Info

Publication number
UA111145C2
UA111145C2 UAA201205788A UAA201205788A UA111145C2 UA 111145 C2 UA111145 C2 UA 111145C2 UA A201205788 A UAA201205788 A UA A201205788A UA A201205788 A UAA201205788 A UA A201205788A UA 111145 C2 UA111145 C2 UA 111145C2
Authority
UA
Ukraine
Prior art keywords
pharmaceutical composition
relates
citric acid
radezolid
prevention
Prior art date
Application number
UAA201205788A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Ерік С. Б'юрак
Данпін Лі
Original Assignee
Мелінта Терап'Ютікс, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мелінта Терап'Ютікс, Інк. filed Critical Мелінта Терап'Ютікс, Інк.
Publication of UA111145C2 publication Critical patent/UA111145C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UAA201205788A 2009-10-13 2010-10-12 Фармацевтична композиція UA111145C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25102309P 2009-10-13 2009-10-13
PCT/US2010/052263 WO2011046905A2 (en) 2009-10-13 2010-10-12 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
UA111145C2 true UA111145C2 (uk) 2016-04-11

Family

ID=43876821

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201205788A UA111145C2 (uk) 2009-10-13 2010-10-12 Фармацевтична композиція

Country Status (16)

Country Link
US (2) US20120208857A1 (enExample)
EP (2) EP2488175A4 (enExample)
JP (3) JP2013507443A (enExample)
KR (1) KR101791709B1 (enExample)
CN (1) CN102573840A (enExample)
AU (2) AU2010307054A1 (enExample)
BR (1) BR112012008649A2 (enExample)
CA (1) CA2776310A1 (enExample)
EA (1) EA022765B1 (enExample)
IL (1) IL219018A (enExample)
MX (1) MX337145B (enExample)
NZ (1) NZ599151A (enExample)
PH (1) PH12012500695A1 (enExample)
SG (1) SG10201406571YA (enExample)
UA (1) UA111145C2 (enExample)
WO (1) WO2011046905A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA027791B1 (ru) 2010-11-24 2017-09-29 Мелинта Терапьютикс, Инк. Фармацевтические композиции
CN104784113B (zh) * 2015-04-30 2017-09-29 成都国为生物医药有限公司 一种含有利奈唑胺的组合物及其制备方法
US11112370B2 (en) * 2019-01-04 2021-09-07 The Boeing Company Reconfigurable backscatter detector

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
MY127336A (en) * 2000-03-22 2006-11-30 Upjohn Co Container for linezolid iv solution
PE20011088A1 (es) * 2000-03-22 2001-10-04 Upjohn Co Tratamiento de infecciones del tracto urinario con oxazolidinonas antibacterianas
NZ522990A (en) 2000-06-05 2003-08-29 Dong A Pharm Novel oxazolidinone derivatives and a process for the preparation thereof
MY137618A (en) * 2000-08-22 2009-02-27 Pharmacia Corp Solution composition of an oxazolidinone antibiotic drug having enhanced drug loading
US6696426B2 (en) * 2000-08-22 2004-02-24 Pharmacia Corporation Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems
PE20020300A1 (es) * 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
TWI378092B (en) 2003-06-03 2012-12-01 Rib X Pharmaceuticals Inc Biaryl heterocyclic compounds and methods of making and using the same
US20060270680A1 (en) * 2003-06-03 2006-11-30 Goldberg Joel A Sulfonamide compounds and methods of making and using the same
JP2007514782A (ja) 2003-12-17 2007-06-07 リブ−エックス ファーマシューティカルズ,インコーポレイテッド ハロゲン化ビアリール複素環式化合物ならびにその作製方法および使用方法
KR100854211B1 (ko) * 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US7696211B2 (en) * 2005-04-29 2010-04-13 Wilson Constance N Methods and pharmaceutical compositions for treating sepsis
US20070249577A1 (en) * 2005-05-10 2007-10-25 Hopkins Scott J Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
WO2007086011A1 (en) * 2006-01-25 2007-08-02 Jegannathan Srinivas Formulation comprising cefepime, tazobactam and linezolid
WO2007133803A2 (en) * 2006-05-15 2007-11-22 Rib-X Pharmaceuticals, Inc. Treatment of mycobacterial infections
WO2008127300A2 (en) * 2006-10-23 2008-10-23 Concert Pharmaceuticals Inc. Oxazolidinone derivatives and methods of use
WO2008085913A1 (en) 2007-01-04 2008-07-17 Rib-X Pharmaceuticals, Inc. Methods for treating, preventing, or reducing the risk of opthalmic, otic, and nasal infections

Also Published As

Publication number Publication date
EP3095445A1 (en) 2016-11-23
PH12012500695A1 (en) 2024-02-12
MX2012004282A (es) 2012-05-22
KR101791709B1 (ko) 2017-10-30
CN102573840A (zh) 2012-07-11
SG10201406571YA (en) 2014-11-27
EA022765B1 (ru) 2016-02-29
KR20120099676A (ko) 2012-09-11
EP2488175A2 (en) 2012-08-22
WO2011046905A3 (en) 2011-10-20
WO2011046905A2 (en) 2011-04-21
EP2488175A4 (en) 2013-08-07
EA201270547A1 (ru) 2012-12-28
IL219018A (en) 2016-11-30
US20120208857A1 (en) 2012-08-16
JP2017141285A (ja) 2017-08-17
AU2010307054A1 (en) 2012-04-26
NZ599151A (en) 2014-07-25
US20150165040A1 (en) 2015-06-18
MX337145B (es) 2016-02-15
JP2013507443A (ja) 2013-03-04
CA2776310A1 (en) 2011-04-21
AU2016234893A1 (en) 2016-10-20
BR112012008649A2 (pt) 2021-11-03
JP2015155479A (ja) 2015-08-27
IL219018A0 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
EA201290191A1 (ru) N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ
UA105911C2 (uk) Сульфонамідні похідні
IL253038A0 (en) Preparations and methods for the treatment or prevention of infections. my voice
DK2315580T3 (da) Farmaceutiske formuleringer og fremgangsmåder til behandling af luftvejsinfektioner
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
EA201200551A1 (ru) Фармацевтическая композиция, фармацевтическая дозированная форма, способы их получения и применения для лечения
MX2011009796A (es) Inhibidores de la cinasa pi3.
MX2013007336A (es) Compuestos de bi-heteroarilo como inhibidores de vps34.
IN2012DN01233A (enExample)
UA105229C2 (uk) Фармацевтичний склад
EA201270741A1 (ru) Пероральные композиции и липофильные соли метилналтрексона
NZ596628A (en) Ketolide compounds having antimicrobial activity
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
MX2012001691A (es) Composiciones de linaclotida que se desintegran oralmente.
MX2009006325A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
PH12020550222A1 (en) Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections
EA201170101A1 (ru) Фармацевтические композиции роувастатина кальция
MX2012007426A (es) Derivados de amino-heteroarilo como bloqueadores de los canales activados por la hiperpolarizacion, controlados por nucleotidos ciclicos.
MX2011011899A (es) Metodo para reducir los niveles proteicos ubiquitinados.
NZ599151A (en) Pharmaceutical composition comprising radezolid or salt thereof and uses thereof
SMT201300112B (it) Sale citrato di 9E-15-(2-pirrolidin-1-il-etossi)-7,12,25-triossa-19,21,24-triaza-tetracicloÄ18.3.1.1(2,5).1(14,18)Üesacos a-1(24),2,4,9,14,16,18(26),20,22-nonaene
PH12013501830A1 (en) Peptide deformylase inhibitors
UA92423C2 (ru) Антибактериальная композиция
PH12013500498A1 (en) Composition for improving brain function and method for improving brain function
EA201390764A1 (ru) Фармацевтические композиции